SANTA BARBARA, Calif., Jan. 3, 2014 (GLOBE NEWSWIRE) -- VG Life Sciences, Inc., (OTC Pink: VGLS) a biotechnology company. Pursuant to a vote of the holders having a majority of the votes of the Company on December 31, 2013, the number of authorized shares of Common Stock of the Company has been increased to 150,000,000.
As required by the State of Delaware, this increase provides the Company with sufficient shares to cover existing obligations and provide for future capital events.
About VG Life Sciences Inc.
Santa Barbara, California-based VG Life Sciences Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious disease, and inflammatory, autoimmune disorders. VGLS controls over 50 US and international patents and pending patents protecting its exclusive biotech platform technologies. For more information and upcoming events, visit www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.
Safe Harbor Statement and Forward-Looking Statements
This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectives and plans of VG Life Sciences will be achieved.
CONTACT: Alexandria Sumner, Corporate Communications VG Life Sciences, Inc. Phone: (805) 679-6763 Email: Alex@vglifesciences.com SOURCE VG Life Sciences, Inc.
Source:VG Life Sciences